Jun 09, 2025
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
May 16, 2025
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
Apr 29, 2025
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
Apr 22, 2025
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
Apr 18, 2025
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
Mar 25, 2025
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Mar 23, 2025
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
Mar 20, 2025
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
Feb 26, 2025
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
Feb 10, 2025
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
Dec 05, 2024
WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations
Nov 13, 2024
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
Oct 28, 2024
WuXi Biologics Launches WuXia(TM) RidGS for Non-Antibiotic Cell Line Development
Sep 23, 2024
WuXi Biologics Included in Hang Seng ESG 50 Index
Aug 08, 2024
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Jul 10, 2024
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
Mar 26, 2024
WuXi Biologics Reports Solid 2023 Annual Results
Mar 05, 2024
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
Jan 31, 2024
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
Jan 24, 2024
WuXi Biologics Launches WuXia ADCC PLUS(TM) for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect